MODERN APPROACHES AND RECENT ADVANCES IN NEUROENDOCRINE TUMORS

Modern Approaches and Recent Advances in Neuroendocrine Tumors-kapak

OVERVIEW OF GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS

Yasin Alper Yıldız

Kastamonu University, Faculty of Medicine, Department of General Surgery, Kastamonu, Türkiye

Yıldız YA. Overview of Gastroenteropancreatic Neuroendocrine Tumors. In: Gönüllü E, Karaman K, editors. Modern Approaches and Recent Advances in Neuroendocrine Tumors. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.3-8.

ABSTRACT

Neuroendocrine tumors are tumoral lesions arising from cells that produce neuroendocrinological secretions. The majority of neuroendocrine tumors are neoplasms that develop in the Gatroenteropancreatic system. Patients generally present with clinical findings depending on the characteristics of the hormonal gland and the hormone it produces. Computed tomography, MRI, hormonal evaluation, PET, endoscopic ultrasound and scintigraphies are used in diagnostic methods. Pathological evaluation, Ki67 index and mitotic staging have an important place in treatment planning. Although surgery is generally preferred in treatment, treatments such as somatostatin analogues, peptide receptor radionuclide therapy, immunotherapy, chemotherapy and IFN-a are used.

Keywords: Neuroendocrine tumors; Gastro-enteropancreatic neuroendocrine tumor; Carcinoma; Neuroendocrine; Malignant carcinoid syndrome

Referanslar

  1. Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. CA Cancer J Clin. 2018 Nov ve 30295930., 68(6):471-487. [Crossref]  [PubMed]
  2. Lu L, Shang Y, Mullins CS, Zhang X, Linnebacher M. Epidemiologic trends and prognostic risk factors of patients with pancreatic neuroendocrine neoplasms in the US: an updated population-based study. Future Oncol. 2021;17(5):549-563. [Crossref]  [PubMed]
  3. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063-72. [Crossref]  [PubMed]
  4. Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770-1786. [Crossref]  [PubMed]  [PMC]
  5. Lu J, Zhao YJ, Zhou Y, He Q, Tian Y, Hao H, et al. on behalf of the Study Group for Gastric Neuroendocrine Tumours. Modified staging system for gastric neuroendocrine carcinoma based on American Joint Committee on Cancer and European Neuroendocrine Tumor Society systems. Br J Surg. 2020;107(3):248-257. [Crossref]  [PubMed]
  6. Leoncini E, Boffetta P, Shafir M, Aleksovska K, Boccia S, Rindi G. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine. 2017;58(2):368-379. [Crossref]  [PubMed]  [PMC]
  7. Zhang XB, Fan YB, Jing R, Getu MA, Chen WY, Zhang W, et al. Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives. Mil Med Res. 2024;11(1):35. [Crossref]  [PubMed]  [PMC]
  8. Delle Fave G, O'Toole D, Sundin A, Taal B, Ferolla P, Ram age JK, et al. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology. 2016;103(2):119-24. [Crossref]  [PubMed]
  9. James PD, Tsolakis AV, Zhang M, Belletrutti PJ, Mohamed R, Roberts DJ, et al. Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis. Gastrointest Endosc. 2015;81(4):848-56.e1. [Crossref]  [PubMed]
  10. Eusebi LH, Thorburn D, Toumpanakis C, Frazzoni L, Johnson G, Vessal S. Endoscopic ultrasound-guided fine-needle aspiration vs fine-needle biopsy for the diagnosis of pancreatic neuroendocrine tumors. Endosc Int Open. 2019;7(11):E1393-E1399. [Crossref]  [PubMed]  [PMC]
  11. Luo Y, Chen X, Chen J, Song C, Shen J, Xiao H, et al. Preoperative Prediction of Pancreatic Neuroendocrine Neoplasms Grading Based on Enhanced Computed Tomography Imaging: Validation of Deep Learning with a Convolutional Neural Network. Neuroendocrinology. 2020;110(5):338-350. [Crossref]  [PubMed]
  12. Han S, Suh CH, Woo S, Kim YJ, Lee JJ. Performance of 68Ga-DOTA-Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis. J Nucl Med. 2019;60(3):369-376. [Crossref]  [PubMed]
  13. Zhang P, Yu J, Li J, Shen L, Li N, Zhu H, et al. Clinical and Prognostic Value of PET/CT Imaging with Combination of 68Ga-DOTATATE and 18F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms. Contrast Media Mol Imaging. 2018;2018:2340389. [Crossref]  [PubMed]  [PMC]
  14. de Mestier L, Lepage C, Baudin E, Coriat R, Courbon F, Couvelard A, et al. Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis. 2020;52(5):473-492. [Crossref]  [PubMed]
  15. Namwongprom S, Wong FC, Tateishi U, Kim EE, Boonyaprapa S. Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors. Ann Nucl Med. 2008;22(4):237-43. [Crossref]  [PubMed]
  16. Kidess E, Giesecke Y, Eichhorn I, et al. Osteopontin is a prognostic circulating biomarker in patients with neuroendocrine neoplasms. J Cancer Res Clin Oncol. 2023;149(12):1092510933. [Crossref]  [PubMed]  [PMC]
  17. Bevilacqua A, Calabrò D, Malavasi S, Ricci C, Casadei R, Campana D, et al. A [68Ga]Ga-DOTANOC PET/CT Radiomic Model for Non-Invasive Prediction of Tumour Grade in Pancreatic Neuroendocrine Tumours. Diagnostics (Basel). 2021 May 12;11(5):870. [Crossref]  [PubMed]  [PMC]
  18. Massironi S, Rossi RE, Casazza G, Conte D, Ciafardini C, Galeazzi M, et al. hromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution. Neuroendocrinology. 2014;100(2-3):240-9. [Crossref]  [PubMed]
  19. Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770-1786. [Crossref]  [PubMed]  [PMC]
  20. Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022;33(1):115-154. [Crossref]  [PubMed]
  21. Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65-71. [Crossref]  [PubMed]
  22. Lindner K, Binte D, Hoeppner J, Wellner UF, Schulte DM, Schmid SM, et al. Resection of Non-Functional Pancreatic Neuroendocrine Neoplasms-A Single-Center Retrospective Outcome Analysis. Curr Oncol. 2021;28(4):3071-3080. [Crossref]  [PubMed]  [PMC]
  23. Pulvirenti A, Pea A, Chang DK, Jamieson NB. Clinical and Molecular Risk Factors for Recurrence Following Radical Surgery of Well-Differentiated Pancreatic Neuroendocrine Tumors. Front Med (Lausanne). 2020;7:385. [Crossref]  [PubMed]  [PMC]
  24. Yang Z, Liu C, Leng K, Liu L, Shi G. Early-onset pancreatic neuroendocrine neoplasms: A distinct disease with improved survival compared with old individuals. Front Endocrinol (Lausanne). 2023;14:1025485. [Crossref]  [PubMed]  [PMC]
  25. Cuthbertson DJ, Shankland R, Srirajaskanthan R. Diagnosis and management of neuroendocrine tumours. Clin Med (Lond). 2023;23(2):119-124. [Crossref]  [PubMed]  [PMC]
  26. Gharios J, Hain E, Dohan A, Prat F, Terris B, Bertherat J, et al. Preand intraoperative diagnostic requirements, ben efits and risks of minimally invasive and robotic surgery for neuroendocrine tumors of the pancreas. Best Pract Res Clin Endocrinol Metab. 2019;33(5):101294. [Crossref]  [PubMed]
  27. Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, et al. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020;49(1):1-33. [Crossref]  [PubMed]  [PMC]
  28. Zilli A, Arcidiacono PG, Conte D, Massironi S. Clinical impact of endoscopic ultrasonography on the management of neuroendocrine tumors: lights and shadows. Dig Liver Dis. 2018;50(1):6-14. [Crossref]  [PubMed]
  29. Zhang J, Jin J, Chen S, Gu J, Zhu Y, Qin K, et al. Minimally invasive distal pancreatectomy for PNETs: laparoscopic or robotic approach? Oncotarget. 2017;8(20):33872-33883. [Crossref]  [PubMed]  [PMC]
  30. Gladdy RA, Strong VE, Coit D, Allen PJ, Gerdes H, Shia J, et al. Defining surgical indications for type I gastric carcinoid tumor. Ann Surg Oncol. 2009;16(11):3154-60. [Crossref]  [PubMed]
  31. Janson ET, Knigge U, Dam G, Federspiel B, Grønbaek H, Stålberg P, et al. Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol. 2021;60(7):931-941. [Crossref]  [PubMed]
  32. Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844-860. [Crossref]  [PubMed]
  33. Yamaguchi T, Takahashi K, Yamada K, Bando H, Baba H, Ito M, et al. A nationwide, multi-institutional collaborative retrospective study of colorectal neuroendocrine tumors in Japan. Ann Gastroenterol Surg. 2020;5(2):215-220. [Crossref]  [PubMed]  [PMC]
  34. Nesti C, Bräutigam K, Benavent M, Bernal L, Boharoon H, Botling J, et al. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study. Lancet Oncol. 2023;24(2):187-194. [Crossref]  [PubMed]
  35. Chan DL, Singh S. Current Chemotherapy Use in Neuroendocrine Tumors. Endocrinol Metab Clin North Am. 2018;47(3):603-614. [Crossref]  [PubMed]
  36. Albertelli M, Dotto A, Nista F, et al. Present and future of immunotherapy in Neuroendocrine Tumors. Rev Endocr Metab Disord. 2021;22:615-636. [Crossref]  [PubMed]  [PMC]
  37. Oberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med. 1983;309(3):129-33. [Crossref]  [PubMed]